Blood-based biomarkers: diagnostic value in brain tumors (focus on gliomas)
Open Access
- 23 October 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1297835
Abstract
Background: Brain tumors, especially gliomas, are known for high lethality. It is currently understood that the correlations of tumors with coagulation and inflammation have been gradually revealed.Objective: This study aimed to explore the potential value of several reported peripheral blood parameters as comprehensively as possible, with preoperative diagnosis and identification of brain tumors (focus on gliomas).Methods: Patients with central nervous system tumors (craniopharyngioma, ependymoma, spinal meningioma, acoustic neuroma, brain metastases, meningioma, and glioma) or primary trigeminal neuralgia admitted to our hospital were retrospectively analyzed. The results of the routine coagulation factor test, serum albumin test, and blood cell test in peripheral blood were recorded for each group of patients on admission. Neutrophil–lymphocyte ratio (NLR), derived NLR (dNLR), platelet–lymphocyte ratio (PLR), lymphocyte–monocyte ratio (LMR), prognostic nutritional index (PNI), the systemic immune-inflammation index (SII), pan-immune-inflammation value (PIV), and their pairings were calculated. Their ability to identify brain tumors and their correlation with glioma grade were analyzed.Results: A total of 698 patients were included in this retrospective case–control study. Glioma patients had higher NLR, SII, and PIV but lower LMR. The NLR in the brain metastasis group was lower than that in the control, meningioma, and acoustic neuroma groups, but the SII and PIV were higher than those in the ependymoma group. Fibrinogen, white blood cell count, neutrophil count, NLR, SII, and PIV in the GBM group were higher than those in the control group. In all comparisons, NLR and NLR + dNLR showed the greatest accuracy, with areas under the curve (AUCs) of 0.7490 (0.6482–0.8498) and 0.7481 (0.6457–0.8505), respectively. PIV, dNLR + PIV, and LMR + PIV ranked second, with AUCs of 0.7200 (0.6551–0.7849), 0.7200 (0.6526–0.7874), 0.7204 (0.6530–0.7878) and 0.7206 (0.6536–0.7875), respectively.Conclusion: NLR, PIV, and their combinations show high sensitivity and specificity in the diagnosis of brain tumors, especially gliomas. Overall, our results provide evidence for these convenient and reliable peripheral blood markers.Keywords
This publication has 36 references indexed in Scilit:
- Diagnostic value of preoperative inflammatory markers in patients with glioma: a multicenter cohort studyJournal of Neurosurgery, 2018
- The Microenvironmental Landscape of Brain TumorsCancer Cell, 2017
- A prospective comparative clinical study of peripheral blood counts and indices in patients with primary brain tumorsJournal of Postgraduate Medicine, 2016
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011Neuro-Oncology, 2014
- New Editorial Team for Neuro-OncologyNeuro-Oncology, 2013
- Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastaseMolecular Cancer, 2013
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Inflammation and cancerNature, 2002
- The Risk of a Diagnosis of Cancer after Primary Deep Venous Thrombosis or Pulmonary EmbolismNew England Journal of Medicine, 1998